HLA-A*0201 & B2M & HPV16-E7

HLA-A*0201 & B2M & HPV16-E7

제품 문의

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
BosakitugBSI-045B; TQC-2731; TQC2731Phase 3 ClinicalBiosion Inc
Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic
상세
EcleralimabCSJ-117; NOV-14Phase 2 ClinicalNovartis Pharma Ag
Asthma; Pulmonary Disease, Chronic Obstructive
상세
WIN-1001XWIN-1001XPhase 2 ClinicalWhanin Pharmaceutical Co Ltd
Nerve Degeneration; Parkinson Disease
상세
PF-07275315PF-07275315Phase 2 ClinicalPfizer Inc
Dermatitis, Atopic
상세
LunsekimigSAR-443765Phase 2 ClinicalSanofi
Nasal Polyps; Asthma; Sinusitis; Inflammation
상세
AZD-8630AZD-8630; AMG-104Phase 2 ClinicalAstrazeneca Plc, Amgen Inc
Asthma
상세
SHR-1905SHR-1905; AIO-001Phase 2 Clinical
Nasal Polyps; Respiratory Tract Diseases; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive
상세
CM-326(Connaught Biomedical Technology)CM-326Phase 2 ClinicalKeymed Biosciences Co Ltd
Nose Diseases; Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic
상세
PF-06342674RN-168; PF-6342674; PF-06342674; ZB-168Phase 1 ClinicalPfizer Inc
Diabetes Mellitus, Type 1; Multiple Sclerosis
상세
HBM-9378SKB378; HBM-9378Phase 1 ClinicalHarbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Asthma
상세
HB-0056HB-0056; HB0056Phase 1 ClinicalShanghai Huaota Biopharmaceutical Co Ltd
Asthma
상세
IBI-3002IBI3002; IBI-3002Phase 1 ClinicalInnovent Biologics(Suzhou) Co Ltd
Asthma
상세
GB-0895GB-0895Phase 1 Clinical
Immune System Diseases; Asthma
상세
STSA-1201STSA-1201; STSA1201Phase 1 Clinical
Asthma
상세
LQ043HLQ043HPhase 1 ClinicalShanghai Novamab Biopharmaceuticals Co Ltd
Asthma
상세
GR2002GR2002Phase 1 ClinicalGenrix (Shanghai) Biopharmaceutical Co Ltd
Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic
상세
QX-008NQX008N; QX-008NPhase 1 ClinicalQyuns Therapeutics Co Ltd
Asthma; Pulmonary Disease, Chronic Obstructive
상세
BD-9BD-9Biolojic Design Inc
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
TezepelumabAMG-157; MEDI-9929ApprovedAmgen IncTezspireUnited StatesAsthmaAstrazeneca Ab2021-12-17
Eosinophilic Esophagitis; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Sinusitis; Asthma; Granulomatosis with Polyangiitis; Lung Diseases; Immune System Diseases; Chronic Urticaria; Respiratory Tract Diseases; Nasal Polyps; Anaphylaxis; Carcinoma; Lung Diseases, Obstructive
상세